• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC NEUROMODULATION INTERSTIM; STIMULATOR, ELECTRICAL, IMPLANTABLE, FOR INCONTINENCE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC NEUROMODULATION INTERSTIM; STIMULATOR, ELECTRICAL, IMPLANTABLE, FOR INCONTINENCE Back to Search Results
Patient Problems Cellulitis (1768); Swelling (2091); Implant Pain (4561)
Event Date 06/09/2023
Event Type  Injury  
Event Description
Had interstim device from medtronic implanted (b)(6) 2022 for oab (overactive bladder), the same week developed cellulitis and was on antibiotics for 10 days.Device wasn't really effective but better than nothing.Had no further issues until (b)(6) 2023 when i had pain and swelling to implantation site.I went to my doctor's office and said i wanted device removed(was on 3 antibiotics for 2 weeks)and had surgery on (b)(6) 2023.I regret ever having this device.In general the er (emergency room) visit on (b)(6) 2023 showed infection and i was prescribed keflex.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
INTERSTIM
Type of Device
STIMULATOR, ELECTRICAL, IMPLANTABLE, FOR INCONTINENCE
Manufacturer (Section D)
MEDTRONIC NEUROMODULATION
MDR Report Key17463311
MDR Text Key320563219
Report NumberMW5120603
Device Sequence Number1
Product Code EZW
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Patient
Type of Report Initial
Report Date 08/01/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Was Device Available for Evaluation? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received08/03/2023
Patient Sequence Number1
Treatment
KEFLEX.
Patient Outcome(s) Required Intervention;
Patient Age54 YR
Patient SexFemale
Patient Weight92 KG
Patient EthnicityNon Hispanic
Patient RaceBlack Or African American
-
-